NCT04755322

Hydroxychloroquine in Prevention of Preeclampsia

Hydroxychloroquine is an Immunomodulator for Improvement of Pregnancy Outcomes in Preeclampsia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Assiut University · Academic / Other
• Sex: Female
• Age: 20 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

Pre-eclampsia complicates up to 8% of pregnancies and is a major contributor to maternal mortality and morbidity The only effective treatment is delivery, which leads to significant neonatal morbidity and mortality if carried out preterm, especially when the disease occurs early in pregnancy. Vascular endothelial dysfunction and immunological impairment are associated with preeclampsia. To date, there is no effective or optimal therapeutic approach for these conditions. Hydroxychloroquine has endothelial protective action via ant diabetic, lipid lowering, antioxidant effects or direct endothelial protection. Hydroxychloroquine is an antimalarial and immunomodulatory agent. In pregnancy, hydroxychloroquine is prescribed for inflammatory conditions associated with adverse perinatal outcomes such as systemic lupus erythematosus, antiphospholipid syndrome and placental inflammatory lesions such as chronic histiocytic intervillositis, hydroxychloroquine has therapeutic potential to improve placental function in pregnancies associated with heightened inflammation.

Conditions

• Preeclampsia

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	Hydroxychloroquine 400 mg at start of pregnancy
DRUG	Folic acid	5 mg
DRUG	Low-dose aspirin	75 mg

Timeline

• Start date: 2021-03-01
• Primary completion: 2023-07-30
• Completion: 2023-07-30
• First posted: 2021-02-16
• Last updated: 2023-12-08

Locations

1 site across 1 country: Egypt